OVARIAN CARCINOMA
Clinical trials for OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cell therapy for solid tumors shows early promise but trial halted
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
New cancer drug trial halted early after testing in just 10 patients
Disease control TerminatedThis early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
Experimental cancer pill tested in 23 patients, study halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
Pfizer's new cancer drug shows early promise in small trial
Disease control TerminatedThis early-stage study tested a new drug, PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung, skin, and kidney cancers. The main goal was to check safety and find the right dose. The study was stopped early, so results are limit…
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis early-phase study tested a new drug (STRO-002) combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal was to check safety and find the right dose. The study was stopped early, so results are limited.
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 19, 2026 11:47 UTC